Can Bayer Meet Monsanto's Demands?

The transcript discusses a company's rejection of an initial offer, seeking a higher price and guarantees on regulatory and financial risks. The buyer has options like raising financing or selling assets to increase the offer. Market reactions vary, with analysts predicting different share prices. The deal could be structured with cash or stock, with cash being more predictable. Concerns include regulatory scrutiny and the buyer's shift from pharma to crop science, affecting investor confidence.

What factors contribute to the regulatory risks associated with the deal?

Why might cash offers be considered more attractive than stock offers in this context?